Could oxytocin reduce autoimmune disease in COVID-19?

Disruption of immune and neuroendocrine system function has been shown to play a key role in COVID-19. Oxytocin is vitally important for the immune and neuroendocrine systems. However, oxytocin dysfunction might occur in COVID-19 leading to autoimmune disease. Intranasal oxytocin may be effective in...

Descripción completa

Detalles Bibliográficos
Autores principales: Diep, Phuoc-Tan, de Kok, Véronique
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier B.V. 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8592845/
https://www.ncbi.nlm.nih.gov/pubmed/34798315
http://dx.doi.org/10.1016/j.autrev.2021.102994
_version_ 1784599566284226560
author Diep, Phuoc-Tan
de Kok, Véronique
author_facet Diep, Phuoc-Tan
de Kok, Véronique
author_sort Diep, Phuoc-Tan
collection PubMed
description Disruption of immune and neuroendocrine system function has been shown to play a key role in COVID-19. Oxytocin is vitally important for the immune and neuroendocrine systems. However, oxytocin dysfunction might occur in COVID-19 leading to autoimmune disease. Intranasal oxytocin may be effective in turning off an overactive immune system. This could be a powerful approach to avoid possible autoimmune diseases after COVID-19.
format Online
Article
Text
id pubmed-8592845
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Elsevier B.V.
record_format MEDLINE/PubMed
spelling pubmed-85928452021-11-16 Could oxytocin reduce autoimmune disease in COVID-19? Diep, Phuoc-Tan de Kok, Véronique Autoimmun Rev Article Disruption of immune and neuroendocrine system function has been shown to play a key role in COVID-19. Oxytocin is vitally important for the immune and neuroendocrine systems. However, oxytocin dysfunction might occur in COVID-19 leading to autoimmune disease. Intranasal oxytocin may be effective in turning off an overactive immune system. This could be a powerful approach to avoid possible autoimmune diseases after COVID-19. Elsevier B.V. 2022-02 2021-11-16 /pmc/articles/PMC8592845/ /pubmed/34798315 http://dx.doi.org/10.1016/j.autrev.2021.102994 Text en © 2021 Elsevier B.V. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
spellingShingle Article
Diep, Phuoc-Tan
de Kok, Véronique
Could oxytocin reduce autoimmune disease in COVID-19?
title Could oxytocin reduce autoimmune disease in COVID-19?
title_full Could oxytocin reduce autoimmune disease in COVID-19?
title_fullStr Could oxytocin reduce autoimmune disease in COVID-19?
title_full_unstemmed Could oxytocin reduce autoimmune disease in COVID-19?
title_short Could oxytocin reduce autoimmune disease in COVID-19?
title_sort could oxytocin reduce autoimmune disease in covid-19?
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8592845/
https://www.ncbi.nlm.nih.gov/pubmed/34798315
http://dx.doi.org/10.1016/j.autrev.2021.102994
work_keys_str_mv AT diepphuoctan couldoxytocinreduceautoimmunediseaseincovid19
AT dekokveronique couldoxytocinreduceautoimmunediseaseincovid19

Ejemplares similares